Colineb for Pseudomonas aeruginosa lung infection in cystic fibrosis
Quick answer: Colineb is used for Pseudomonas aeruginosa lung infection in cystic fibrosis as part of a polymyxin antibiotic (inhaled) treatment regimen. Colistimethate sodium disrupts bacterial cell membrane permeability in Gram-negative bacteria The specific dosing for Pseudomonas aeruginosa lung infection in cystic fibrosis is determined by your prescriber based on individual factors.
Why is Colineb used for Pseudomonas aeruginosa lung infection in cystic fibrosis?
Colineb belongs to the Polymyxin antibiotic (inhaled) class. Colistimethate sodium disrupts bacterial cell membrane permeability in Gram-negative bacteria This action makes it useful for treating or managing Pseudomonas aeruginosa lung infection in cystic fibrosis in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Colineb is the right choice for a specific patient depends on the type and severity of Pseudomonas aeruginosa lung infection in cystic fibrosis, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Pseudomonas aeruginosa lung infection in cystic fibrosis
Common adult dosing range: 1-2 million IU nebulized twice daily. The actual dose for Pseudomonas aeruginosa lung infection in cystic fibrosis depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Colineb medicine page.
What to expect
Colineb treatment for Pseudomonas aeruginosa lung infection in cystic fibrosis typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Pseudomonas aeruginosa lung infection in cystic fibrosis
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Colineb is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Polymyxin antibiotic (inhaled) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Colineb
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Colineb full prescribing information · All Polymyxin antibiotic (inhaled) alternatives
Frequently asked questions
How effective is Colineb for Pseudomonas aeruginosa lung infection in cystic fibrosis?
Effectiveness varies by individual response, dose, and severity. Colineb is one of several treatment options for Pseudomonas aeruginosa lung infection in cystic fibrosis, supported by clinical evidence within the polymyxin antibiotic (inhaled) class. Discuss expected response with your prescriber.
How long do I need to take Colineb for Pseudomonas aeruginosa lung infection in cystic fibrosis?
Treatment duration depends on the nature of Pseudomonas aeruginosa lung infection in cystic fibrosis — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Colineb when used for Pseudomonas aeruginosa lung infection in cystic fibrosis?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Colineb for Pseudomonas aeruginosa lung infection in cystic fibrosis?
Yes. Multiple medicines and non-drug options exist for Pseudomonas aeruginosa lung infection in cystic fibrosis. Alternatives within the polymyxin antibiotic (inhaled) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.